0000882291
false
0000882291
2023-08-10
2023-08-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 10, 2023
AETHLON
MEDICAL, INC.
(Exact name of Registrant as Specified in Its
Charter)
Nevada |
001-37487 |
13-3632859 |
(State or Other Jurisdiction of
Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
11555
Sorrento Valley Road, Suite
203
San Diego, California |
92121 |
(Address of Principal Executive Offices) |
(Zip Code) |
Registrant’s Telephone Number, Including
Area Code: (619) 941-0360
N/A
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $0.001 par value per share |
AEMD |
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 2.02 |
Results of Operations and Financial Condition. |
On August 10, 2023, Aethlon Medical, Inc. issued
a press release announcing its financial results for the quarter ended June 30, 2023. A copy of this press release is attached hereto
as Exhibit 99.1.
The information in this Item 2.02 and the exhibit
hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth
by specific reference in such a filing.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 10, 2023 |
Aethlon Medical, Inc. |
|
|
|
|
|
|
|
By: |
|
/s/ James B. Frakes |
|
Name:
|
|
James B. Frakes
Chief Financial Officer |
Exhibit 99.1
Aethlon Medical
Announces Fiscal First Quarter Financial Results and Provides Corporate Update
Conference
Call to be Held Today at 4:30 p.m. ET
SAN DIEGO, August 10, 2023 -- Aethlon Medical,
Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases,
today reported financial results for its fiscal first quarter ended June 30, 2023 and provided an update on recent developments.
Company Updates
Aethlon Medical is continuing the research and
clinical development of its Hemopurifier®, a therapeutic blood filtration system that can bind and remove harmful exosomes
and life-threatening viruses from blood. Aethlon also recently announced that it is investigating the use of the Hemopurifier in the organ
transplant setting, initially focusing on the potential removal of harmful viruses and exosomes from recovered kidneys. These qualities
of the Hemopurifier have potential applications in oncology, where cancer associated exosomes may promote immune suppression and metastasis,
and in life-threatening infectious diseases and the organ transplant field.
The company’s ongoing COVID-19 trial in
India, for patients in the intensive care unit (ICU) at Medanta Medicity Hospital, remains open for enrollment, with one patient treated
to date. In May 2023, a second clinical site, Maulana Azad Medical College (MAMC), received Ethics Board Approval to participate in the
trial and site activation activities are currently underway. Patients with COVID-19 infections that require hospitalization continue to
occur in India, and the addition of MAMC as a second, high quality clinical site, may improve the enrollment of patients who go on to
require ICU care for severe infection.
In the oncology indication, Aethlon Medical continues
to work with its contract research organization, North American Science Associates, LLC (NAMSA), to initiate a clinical study in Australia;
specifically, a safety, feasibility and dose finding trial in solid tumors failing treatment with anti-PD-1 antibodies. Aethlon Medical
believes that the data generated from this trial will help inform the design of future oncology efficacy trials of the company’s
Hemopurifier. Ongoing activities include site identification and qualification, finalization of necessary documents for Ethics Board submission,
case report form development and selection of a Data Safety Monitoring Board.
The company recently announced that it has begun
investigating the use of the Hemopurifier in the organ transplant setting. The objective is to confirm that the Hemopurifier, in translational
studies, when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses and exosomes from recovered
kidneys. In July, the company signed a research collaboration agreement with 34 Lives, PBC, to investigate the use of our proprietary
Hemopurifier and 34 Lives' organ evaluation and preservation system, with the goal of increasing the supply of useable donated kidneys
for human transplant. The company has previously demonstrated the removal of multiple viruses and exosomes from buffer solutions, in vitro,
utilizing a scaled-down version of our Hemopurifier. This process may potentially reduce complications following transplantation of the
recovered organ, which can include viral infection, delayed graft function and rejection. The company believes that this new approach
could be additive to existing technologies that currently are in place to meaningfully increase the number of viable kidneys for transplant.
Financial Results for the First Quarter Ended
June 30, 2023
As of June 30, 2023, Aethlon Medical had a cash
balance of approximately $12.9 million.
During the first quarter ended June 30, 2023,
the company raised net proceeds of approximately $1.1 million under the company’s at-the-market agreement with H. C. Wainwright
& Co.
Consolidated operating expenses for the three
months ended June 30, 2023 were approximately $3.4 million, compared to $2.9 million for the three months ended June 30, 2022. This increase
of approximately $0.5 million, or 17.3%, in the 2023 period was due to increases in general and administrative expenses of approximately
$276,000, professional fees of $133,000 and in payroll and related expenses of approximately $91,000.
The $276,000 increase in general and administrative
expenses was primarily due to a combination of factors. Those factors included a $344,000 increase in purchase of raw materials for production
of the company’s Hemopurifier, $133,000 increase related to the Australian subsidiary’s activities, a $105,000 increase in
depreciation and equipment maintenance associated with leasehold improvements and new equipment for manufacturing and lab facilities,
and an increase of $14,000 in insurance expense. These increases were partially offset by a $160,000 decrease in clinical trial expenses,
a $140,000 decrease in subcontract expense associated with government contracts and a net decrease of $29,000 in expenses related to our
previously rented mobile cleanroom.
The $133,000 increase in professional fees was
due to an increase of $123,000 in investor relations expenses associated with facilitating investor awareness and assistance with more
widespread dissemination of Company news, an increase of $37,000 associated with accounting and legal services for our Australian subsidiary
and $86,000 of legal expenses associated with year-end filings and general corporate matters. Increases were offset by decreases in regulatory
services of $85,000, recruiting expense of $28,000 and $6,000 in consulting services.
The $91,000 increase in payroll expense was due
to $56,000 in salary expense related to an increase in headcount and a $35,000 increase in stock based compensation related to employee
stock option grants.
As a result of the above factors, the company’s
net loss increased to approximately $3.3 million in the three months ended June 30, 2023, from approximately $2.9 million in the three
months ended June 30, 2022.
The condensed consolidated balance sheet for June
30, 2023, and the condensed consolidated statements of operations for the three month periods ended June 30, 2023 and 2022 follow at the
end of this release.
Conference Call
Aethlon
Medical will hold a conference call today, Thursday, August 10, 2023, at 4:30 p.m. ET to review its financial results for its first quarter
ended June 30, 2023 and recent corporate developments. Interested parties can register for the conference by navigating to https://dpregister.com/sreg/10181673/fa26a9fc02.
Please note that registered participants will receive their dial-in number upon registration.
Interested parties without internet access or
who are unable to pre-register, may dial in as follows:
Participant Dial In (Toll Free): 1-844-836-8741
Participant International Dial In: 1-412-317-5442
All callers should ask for the Aethlon Medical,
Inc. conference call.
A replay of the call will be available approximately
one hour after the end of the call through September 10, 2023. The replay can be accessed via Aethlon Medical's website or by dialing
1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is
7051036.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company
focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening
viral infections. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from
blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote
immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration
(FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive
to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development
or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption
(IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Additional information can be found at www.AethlonMedical.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that
involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect,"
"intend," "plan," "project," "will," "projections," "estimate," "potentially"
or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties
and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements
are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors
that may contribute to such differences include, without limitation, the Company's ability to successfully complete development of the
Hemopurifier and to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases and in the transplant setting,
the Company’s ability to manage and successfully complete its clinical trials, the Company’s ability to raise additional capital,
and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that
could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk
Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2023, and in the Company's other filings with the
Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it
undertake any duty, to update this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
AETHLON MEDICAL, INC. AND SUBSIDIARY
Condensed Consolidated Balance Sheets
ASSETS |
|
|
|
|
|
|
|
|
| |
June 30, 2023 | | |
March 31, 2023 | |
| |
(unaudited) | | |
| |
CURRENT ASSETS | |
| | | |
| | |
Cash | |
$ | 12,897,734 | | |
$ | 14,532,943 | |
Prepaid expenses | |
| 410,223 | | |
| 557,623 | |
| |
| | | |
| | |
TOTAL CURRENT ASSETS | |
| 13,307,957 | | |
| 15,090,566 | |
| |
| | | |
| | |
Property and equipment, net | |
| 1,284,200 | | |
| 1,144,004 | |
Right-of-use lease asset | |
| 1,086,108 | | |
| 1,151,909 | |
Patents, net | |
| 1,513 | | |
| 1,650 | |
Restricted cash | |
| 87,506 | | |
| 87,506 | |
Deposits | |
| 33,305 | | |
| 33,305 | |
| |
| | | |
| | |
TOTAL ASSETS | |
$ | 15,800,589 | | |
$ | 17,508,940 | |
| |
| | | |
| | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |
| | | |
| | |
| |
| | | |
| | |
CURRENT LIABILITIES | |
| | | |
| | |
Accounts payable | |
$ | 844,536 | | |
$ | 432,890 | |
Due to related parties | |
| 191,314 | | |
| 214,221 | |
Lease liability, current portion | |
| 274,520 | | |
| 269,386 | |
Other current liabilities | |
| 511,377 | | |
| 588,592 | |
| |
| | | |
| | |
TOTAL CURRENT LIABILITIES | |
| 1,821,747 | | |
| 1,505,089 | |
| |
| | | |
| | |
Lease liability, less current portion | |
| 869,945 | | |
| 939,642 | |
| |
| | | |
| | |
TOTAL LIABILITIES | |
| 2,691,692 | | |
| 2,444,731 | |
| |
| | | |
| | |
COMMITMENTS AND CONTINGENCIES | |
| | | |
| | |
| |
| | | |
| | |
EQUITY | |
| | | |
| | |
| |
| | | |
| | |
Common stock, par value of $0.001, 60,000,000 shares authorized; 24,835,321 and
22,992,466 issued and outstanding | |
| 24,837 | | |
| 22,994 | |
Additional-paid in capital | |
| 158,731,929 | | |
| 157,405,911 | |
Accumulated other comprehensive loss | |
| (7,135 | ) | |
| (6,141 | ) |
Accumulated deficit | |
| (145,640,734 | ) | |
| (142,358,555 | ) |
| |
| | | |
| | |
TOTAL STOCKHOLDERS' EQUITY BEFORE NONCONTROLLING INTERESTS | |
| 13,108,897 | | |
| 15,064,209 | |
| |
| | | |
| | |
Noncontrolling interests | |
| – | | |
| – | |
| |
| | | |
| | |
TOTAL STOCKHOLDERS' EQUITY | |
| 13,108,897 | | |
| 15,064,209 | |
| |
| | | |
| | |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | |
$ | 15,800,589 | | |
$ | 17,508,940 | |
AETHLON MEDICAL, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
For the three month periods ended June 30, 2023 and 2022
| |
Three Months | | |
Three Months | |
| |
Ended 6/30/23 | | |
Ended 6/30/22 | |
| |
| | |
| |
OPERATING COSTS AND EXPENSES | |
| | | |
| | |
Professional fees | |
$ | 976,638 | | |
$ | 844,028 | |
Payroll and related | |
| 1,123,239 | | |
| 1,029,686 | |
General and administrative | |
| 1,308,283 | | |
| 1,032,367 | |
Total Operating Expenses | |
| 3,408,160 | | |
| 2,906,081 | |
| |
| | | |
| | |
OPERATING LOSS | |
| (3,408,160 | ) | |
| (2,906,081 | ) |
| |
| | | |
| | |
OTHER INCOME | |
| | | |
| | |
Interest income | |
| 125,981 | | |
| – | |
| |
| 125,981 | | |
| – | |
| |
| | | |
| | |
NET LOSS BEFORE NONCONTROLLING INTERESTS | |
$ | (3,282,179 | ) | |
$ | (2,906,081 | ) |
| |
| | | |
| | |
Loss attributable to noncontrolling interests | |
| – | | |
| (413 | ) |
| |
| | | |
| | |
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | |
$ | (3,282,179 | ) | |
$ | (2,905,668 | ) |
| |
| | | |
| | |
OTHER COMPREHENSIVE LOSS | |
| (994 | ) | |
| – | |
| |
| | | |
| | |
COMPREHENSIVE LOSS | |
$ | (3,283,173 | ) | |
$ | (2,905,668 | ) |
| |
| | | |
| | |
Basic and diluted net loss available to common stockholders per share | |
$ | (0.14 | ) | |
$ | (0.19 | ) |
| |
| | | |
| | |
Weighted average number of common shares outstanding | |
| 24,314,759 | | |
| 15,486,621 | |
v3.23.2
Cover
|
Aug. 10, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 10, 2023
|
Entity File Number |
001-37487
|
Entity Registrant Name |
AETHLON
MEDICAL, INC.
|
Entity Central Index Key |
0000882291
|
Entity Tax Identification Number |
13-3632859
|
Entity Incorporation, State or Country Code |
NV
|
Entity Address, Address Line One |
11555
Sorrento Valley Road
|
Entity Address, Address Line Two |
Suite
203
|
Entity Address, City or Town |
San Diego
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
92121
|
City Area Code |
619
|
Local Phone Number |
941-0360
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, $0.001 par value per share
|
Trading Symbol |
AEMD
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Aethlon Medical (NASDAQ:AEMD)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Aethlon Medical (NASDAQ:AEMD)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024